Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
boston blog main
4
×
clinical trials
life sciences
national blog main
biotech
boston top stories
fda
national top stories
new york blog main
new york top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
abbvie
acorda therapeutics
aimmune therapeutics
akcea therapeutics
allergy
alnylam pharmaceuticals
alprazolam
amgen
ampyra
anaphylaxis
andrew oxtoby
apokyn
apomorphine
barry greene
boston
boston university
boulder/denver blog main
boulder/denver top stories
cgrp inhibitors
chronic migraine
colucid pharmaceuticals
dalfampridine
What
fda
friday
4
×
drug
approval
approved
decades
late
new
patients
time
won
acorda
acute
addresses
agency
ago
aimmune
allergy
alnylam
approve
awaits
awarded
biological
causes
condition
cope
crossed
decision
developed
discovered
disease
eli
episodes
fingers
gets
giant
giving
help
historic
immunotherapy
Language
unset
Current search:
friday
×
photo
×
" boston blog main "
×
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision